# US 2003/0228667 A1 · Nucleotide sequence encoding a modulator of NF-kappaB

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0228667 A1
- Document ID: US20030228667A1
- Status: Published application
- Kind: A1
- Application number: 10/408,305
- Filed: 2003-04-08
- Published: 2003-12-11
- Earliest claimed: 1999-02-22
- Assignees: Institut Pasteur
- Inventors: Shoji Yamaoka; Gilles Courtois; Alain Israel; Robert Weil
- Web page: https://patentgrep.com/patent/US20030228667A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 16/18: against material from animals or humans
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to nucleotide sequences encoding a modulator of NF-κB, and to the polypeptides encoded by the nucleotide sequences. In particular, the invention relates to nucleotide sequences and the polypeptides encoded thereby, wherein the polypeptides are involved in the response to NF-κB-activating stimuli, including HTLV-1 Tax, LPS, PMA and IL-1. The invention also relates to antibodies to the modulator of NF-κB, methods of detecting modulator of NF-κB using the antibodies, methods of treatment associated with NF-κB activation and to methods of identifying compounds which modulate the activity of the modulator of NF-κB.

## Claims

### Claim 1

A purified modulator of NF-κB, comprising a material selected from the group consisting of a protein, active fragments thereof, agonists thereof, mimics thereof, and combinations thereof, said modulator having the following characteristics:
a) an apparent molecular weight of approximately 48 kD;
b) a pI of approximately 5.66;
c) containing a leucine zipper motif; and
d) binding to a kinase involved in the activation of NF-κB.

### Claim 2 (depends on 1)

The purified modulator of NF-κB of claim 1 which is a polypeptide comprising SEQ ID NO:1.

### Claim 3 (depends on 1)

The purified modulator of NF-κB of claim 1 which is deficient in rat 5R cell line and in murine pre-B cell line 1.3E2.

### Claim 4 (depends on 1)

The purified modulator of NF-κB of claim 1 labeled with a detectable label.

### Claim 5 (depends on 4)

The purified modulator of NF-κB of claim 4 wherein the label is selected from enzymes, chemicals which fluoresce and radioactive elements.

### Claim 6

An antibody to a purified modulator of NF-κB, the purified modulator of NF-κB to which said antibody is raised having the following characteristics:
a) an apparent molecular weight of approximately 48 kD;
b) a pI of approximately 5.66;
c) containing a leucine zipper motif; and
d) binding to a kinase involved in the activation of NF-κB.

### Claim 7 (depends on 6)

The antibody of claim 6 which is a polyclonal antibody.

### Claim 8 (depends on 6)

The antibody of claim 6 which is a monoclonal antibody.

### Claim 9 (depends on 8)

An immortal cell line that produces a monoclonal antibody according to claim 8.

### Claim 10 (depends on 6)

The antibody of claim 6 labeled with a detectable label.

### Claim 11 (depends on 10)

The antibody of claim 10 wherein the label is selected from enzymes, chemicals which fluoresce and radioactive elements.

### Claim 12 (depends on 1)

A purified DNA sequence which encodes a purified modulator of NF-κB, or a fragment thereof which binds to a component of an IκB kinase, selected from the group consisting of:
(A) the DNA sequence SEQ ID NO:______;
(B) DNA sequences that hybridize to the DNA sequence of (A) under standard hybridization conditions; and
(C) DNA sequences that encode the protein of claim 1.

### Claim 13 (depends on 12)

A recombinant DNA molecule comprising the purified DNA sequence of claim 12.

### Claim 14 (depends on 13)

The recombinant DNA molecule of claim 13, wherein said DNA sequence is operatively linked to an expression control sequence.

### Claim 15 (depends on 14)

The recombinant DNA molecule of claim 14, wherein said expression control sequence is selected from the group consisting of the early or late promoters of CMV, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage λ, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase and the promoters of the yeast α-mating factors.

### Claim 16 (depends on 12)

A probe capable of screening for a DNA sequence encoding a modulator of NF-κB in alternate species, wherein said probe is a fragment of the purified DNA sequence of claim 12 which binds to the DNA sequence encoding a modulator of NF-κB in alternate species under standard hybridization conditions.

### Claim 17 (depends on 14)

A unicellular host transformed with the recombinant DNA molecule of claim 14.

### Claim 18 (depends on 17)

The unicellular host of claim 17 wherein the unicellular host is selected from the group consisting of E. coli, Pseudomonas, Bacillus, Streptomyces, yeasts, CHO, R1.1, B-W, L-M, COS 1, COS 7, BSC1, BSC40, and BMT10 cells, plant cells, insect cells, and human cells in tissue culture.

### Claim 19 (depends on 1, 17)

A method for producing the modulator of NF-κB of claim 1 comprising:
(a) culturing the unicellular host of claim 17; and
(b) isolating the modulator of NF-κB from said cultured unicellular host.

### Claim 20 (depends on 1)

A method for detecting the presence or activity of the modulator of NF-κB of claim 1, comprising the steps of:
A. contacting a biological sample from a mammal in which the presence or activity of said modulator of NF-κB is suspected with a binding partner of said modulator of NF-κB under conditions that allow binding of said modulator of NF-κB to said binding partner to occur; and
B. detecting whether binding has occurred between said modulator of NF-κB from said sample and the binding partner; and
C. correlating the detection of binding to the presence or activity of said modulator of NF-κB in said sample.

### Claim 21 (depends on 20)

A method for detecting the presence and activity of an activator of NF-κB comprising detecting the presence or activity of a modulator of NF-κB according to the method of claim 20, wherein detection of the presence or activity of the modulator of NF-κB indicates the presence and activity of an activator of NF-κB.

### Claim 22 (depends on 21)

The method of claim 21 wherein said activator of NF-κB is lipopolysaccharide (LPS), phorbol myristate acetate (PMA), interleukin-1 (IL-1) and HTLV-I Tax.

### Claim 23 (depends on 1)

A method for detecting binding of a molecule to the modulator of NF-κB of claim 1 comprising:
A. contacting a labeled molecule, the binding of which to the modulator of NF-κB is to be detected, with the purified modulator of NF-κB of claim 1;
B. detecting the label bound to the purified modulator of NF-κB of claim 1;
C. correlating the presence of said labeled molecule to the ability of said molecule to bind to the purified modulator of claim 1.

### Claim 24 (depends on 1)

A method of testing the ability of a drug or other entity to modulate the activity of the modulator of NF-κB of claim 1 which comprises;
A. adding the drug or other entity to cultured cells;
B. measuring the level of binding of NF-κB to DNA following stimulation of the cultured cells; and
C. correlating a decrease in the level of binding of NF-κB to DNA with inhibition of said modulator of NF-κB.

### Claim 25 (depends on 1)

A test kit for the demonstration of the modulator of NF-κB of claim 1 in a eukaryotic cellular sample, comprising:
A. a predetermined amount of a detectably labeled specific binding partner of the modulator of NF-κB of claim 1;
B. other reagents; and
C. directions for use of said kit.

### Claim 26 (depends on 1)

A test kit for demonstrating the presence of the modulator of NF-κB of claim 1 in a eukaryotic cellular sample, comprising:
A. a predetermined amount of the modulator of NF-κB of claim 1;
B. a predetermined amount of a specific binding partner of said modulator of NF-κB of claim 1;
C. other reagents; and
D. directions for use of said kit;
wherein either said modulator of NF-κB or said specific binding partner are detectably labeled.

### Claim 27 (depends on 25, 26)

The test kit of claim 25 or 26 wherein said labeled immunochemically reactive component is selected from the group consisting of polyclonal antibodies to the modulator of NF-κB, monoclonal antibodies to the modulator of NF-κB, fragments thereof, and mixtures thereof.

### Claim 28 (depends on 1)

A method of preventing and/or treating cellular debilitations, derangements and/or dysfunctions and/or other disease states in mammals, wherein said cellular debilitations, derangements and/or dysfunctions and/or other disease states are caused by activation of NF-κB, comprising administering to a mammal a therapeutically effective amount of a material selected from the group consisting of the modulator of NF-κB of claim 1, an agent capable of modulating the production and/or activity of said modulator of NF-κB, an agent capable of mimicking the activity of said modulator of NF-κB, an agent capable of modulating the production of said modulator of NF-κB, and mixtures thereof.

### Claim 29 (depends on 28)

The method of claim 28 wherein said cellular debilitations, derangements and/or dysfunctions and/or other disease states include immune responses, stress responses, inflammation or apoptosis.

### Claim 30 (depends on 1)

A pharmaceutical composition for the treatment of cellular debilitation, derangement and/or dysfunction in mammals, comprising:
A. a therapeutically effective amount of a material selected from the group consisting of the modulator of NF-κB of claim 1, an agent capable of modulating the production and/or activity of said modulator of NF-κB, an agent capable of mimicking the activity of said modulator of NF-κB, an agent capable of modulating the production of said modulator of NF-κB, and mixtures thereof, or a specific binding partner thereto; and
B. a pharmaceutically acceptable carrier.

### Claim 31 (depends on 12)

A recombinant virus transformed with the DNA molecule of claim 12.

### Claim 32 (depends on 1)

A method of inhibiting NF-κB activity in a mammal in need of such treatment, comprising administering to said mammal an effective amount of the modulator of NF-κB of claim 1, wherein said modulator of NF-κB inhibits the phosphorylation of intracellular IκB proteins.

### Claim 33

A method of determining the ability of a pharmacological agent to enhance the activity of a modulator of NF-κB comprising:
administering the pharmacological agent to a first mammal;
comparing the activity of the modulator of NF-κB to a sample from a second mammal to which the pharmacological agent is not administered.

### Claim 34 (depends on 1)

An antisense nucleic acid against an mRNA encoding the modulator of NF-κof claim 1 comprising a nucleic acid sequence hybridizing to said mRNA.

### Claim 35 (depends on 34)

The antisense nucleic acid of claim 34 which is RNA.

### Claim 36 (depends on 35)

The antisense nucleic acid of claim 35 which is DNA.

### Claim 37 (depends on 35)

The antisense nucleic acid of claim 35 which binds to the initiation codon of said mRNA.

### Claim 38 (depends on 1)

A recombinant DNA molecule having a DNA sequence which, on transcription, produces an antisense ribonucleic acid against an mRNA encoding the modulator of NF-κB of claim 1, said antisense ribonucleic acid comprising an nucleic acid sequence capable of hybridizing to said mRNA.

### Claim 39 (depends on 38)

A cell line transfected with the recombinant DNA molecule of claim 38.

### Claim 40 (depends on 38)

A method for creating a cell line which exhibits reduced transcriptional activity, comprising transfecting an NF-κB-producing cell line with the recombinant DNA molecule of claim 38.

### Claim 41 (depends on 1)

A ribozyme that cleaves mRNA encoding the modulator of NF-κB of claim 1.

### Claim 42 (depends on 41)

The ribozyme of claim 41 which is a Tetrahymena-type ribozyme.

### Claim 43 (depends on 41)

The ribozyme of claim 41 which is a Hammerhead-type ribozyme.

### Claim 44 (depends on 41)

A recombinant DNA molecule having a DNA sequence which, upon transcription, produces the ribozyme of claim 41.

### Claim 45 (depends on 44)

An NF-κB-producing cell line transfected with the recombinant DNA molecule of claim 44.

### Claim 46 (depends on 44)

A method for creating a cell line which exhibits reduced transcriptional activity, comprising transfecting an NF-κB-producing cell line with the recombinant DNA molecule of claim 44.

### Claim 47 (depends on 20)

A compound which competes with a purified modulator of NF-κB, wherein said modulator of NF-κB comprises a material selected from the group consisting of a protein, active fragments thereof, agonists thereof, mimics thereof, and combinations thereof, said modulator having the following characteristics:
a) an apparent molecular weight of approximately 48 kD;
b) a pI of approximately 5.66;
c) containing a leucine zipper motif; and
d) binding to a kinase involved in the activation of NF-κselected by the process of claim 20.

### Claim 48 (depends on 21)

A compound which competes with a purified modulator of NF-κB, wherein said modulator of NF-κB comprises a material selected from the group consisting of a protein, active fragments thereof, agonists thereof, mimics thereof, and combinations thereof, said modulator having the following characteristics:
a) an apparent molecular weight of approximately 48 kD;
b) a pI of approximately 5.66;
c) containing a leucine zipper motif; and
d) binding to a kinase involved in the activation of NF-κB, selected by the process of claim 21.

### Claim 49 (depends on 23)

A compound which competes with a purified modulator of NF-κB, wherein said modulator of NF-κB comprises a material selected from the group consisting of a protein, active fragments thereof, agonists thereof, mimics thereof, and combinations thereof, said modulator having the following characteristics:
a) an apparent molecular weight of approximately 48 kD;
b) a pI of approximately 5.66;
c) containing a leucine zipper motif; and
d) binding to a kinase involved in the activation of NF-κB, selected by the process of claim 23.

### Claim 50 (depends on 24)

A compound which competes with a purified modulator of NF-κB, wherein said modulator of NF-κB comprises a material selected from the group consisting of a protein, active fragments thereof, agonists thereof, mimics thereof, and combinations thereof, said modulator having the following characteristics:
a) an apparent molecular weight of approximately 48 kD;
b) a pI of approximately 5.66;
c) containing a leucine zipper motif; and
d) binding to a kinase involved in the activation of NF-κB, selected by the process of claim 24.
